PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care

• Status: Completed
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to conduct a trial in the spirit of providing as much as possible the benefit of PG2 treatment to eligible patients and to evaluate the efficacy and safety of different doses of PG2 treatment for relieving fatigue among advanced cancer patients who are under standard palliative care (SPC) at hospice setting and have no further curative options available. Patient's fatigue status, to be measured by the Brief Fatigue Inventory-Taiwanese Form (BFI-T), will be the primary endpoint. The fatigue improvement response rate among patients between two study arms will then be compared as the basis for efficacy evaluation at the end of the first treatment cycle, and will be the primary endpoint. Other endpoints, the fatigue improvement response rate and the mean fatigue scores change from baseline among patients within and between cycles will be included in the secondary efficacy endpoints, and will be compared between two study arms. Patients' quality of sleep, appetite, pain, fatigue, nausea, vomiting and global quality of life (QoL) will be also measured by 11 questions (SS11) from EORTC(European Organization) for Research and Treatment of Cancer QLQ-C30 for secondary endpoint evaluation. The other secondary endpoints include Karnofsky performance scores, and weight change and its related c-reactive protein level of the patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PhytoHealth Corporation

Criteria

Inclusion Criteria:

• Signed the informed consent form

• ≧ 20 years old

• Have locally advanced or metastatic cancer or inoperable advanced cancer

• Under standard palliative care (SPC) at hospice setting and have no further curative options available

• BFI score ≧ 4

• Life expectancy of at least 3 months as determined by the investigator

• Willing and able to complete quality of life questionnaires

Exclusion Criteria:

• Pregnant or breast-feeding

• Uncontrolled systemic disease

• Take central nervous system stimulators within 30 days before screening

• Have enrolled or have not yet completed other investigational drug trials within 30 days before screening

• Karnofsky Performance Scores less than 30 %

• Diagnosed as dying status